Is cannabinol (CBN) a sleep aid?

by Duncan Fisher

October 19, 2022 - 2 min read

Cannabinol (CBN) was the first phytocannabinoid to be identified, in the 1930’s. It is unique among cannabis derivatives for not occurring in acid form in the plant. It is a product of THC degradation through light, oxygen, and heat. It is a partial agonist of the CB1 receptor, and for this reason, supposedly, it has a reputation for inducing sleep-related effects – up to 10 times stronger than over-the-counter sleeping preparations, according to some advertising copy. 

This reputation is not justified by preclinical or clinical research evidence so far. It is not impossible that a partial agonist of the CB1 receptor, like CBN, could cause sleepiness. THC, which is also a low-affinity CB1 agonist, does do this. But so far the published evidence that CBN causes drowsiness – or any of the other effects of cannabis – does not exist. Most of the human studies of any aspect of CBN date to the 1970’s and 1980’s, and involve very small sample sizes, with extremely narrow demographics. Studies addressing CBN’s sleep effects specifically are vanishingly rare. There are in fact no published trials of CBN against validated sleep questionnaires or polysomnographic analysis at all. 

There is only one registered trial investigating CBN for sleep currently; it is in the recruiting stage as of the date of this writing, and has not yet begun. This will bea randomised, double-blind, placebo-controlled, single-dose, crossover study of cannabinol’s effects on sleep architecture and next-day functioning in diagnosed Insomnia Disorder. This study will evaluate polysomnography metrics. 


DiolPure products contain PureForm CBD™ transformed from aromatic terpenes for pharmaceutical-grade purity. PureForm CBD™ is bioidentical to CBD extracted from hemp and cannabis, but free of any residual cannabinoids like THC or impurities or chemicals that can associate with traditional plant-derived production processes. 

The foregoing is a report on trends and developments in cannabinoid industry research. No product description herein is intended as a recommendation for diagnosis, treatment, cure or prevention of any disease or syndrome. 


Beyond glaucoma: Cannabinoids in ophthalmology

Beyond glaucoma: Cannabinoids in ophthalmology

Cannabinoids appear to have therapeutic potential in glaucoma. Beyond this, there may be further promise in ophthalmology.
Read More

December 05, 2022 1 min read

The endocannabinoid system and bone disease

The endocannabinoid system and bone disease

Stimulation of the endocannabinoid system modulates bone formation and bone resorption. There may be a role one day for targeted drugs in osteoporosis and some forms of bone cancer. 
Read More

December 02, 2022 1 min read

Sex differences, endocannabinoids, and pain

Sex differences, endocannabinoids, and pain

Sex differences in pain perception and analgesia is a burgeoning research field overall. What about cannabinoid analgesia specifically? 
Read More

December 01, 2022 2 min read

Follow us on Instagram

Net Orders Checkout

Item Price Qty Total
Subtotal $ 0.00

Shipping Address

Shipping Methods